All Information (Except Text) for S.3630 - Facilitating Innovation to Fight Coronavirus Act116th Congress (2019-2020) |
|Sponsor:||Sen. Sasse, Ben [R-NE] (Introduced 05/06/2020)|
|Committees:||Senate - Judiciary|
|Latest Action:||Senate - 05/06/2020 Read twice and referred to the Committee on the Judiciary. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
- Passed Senate
- Passed House
- To President
- Became Law
There is 1 version of this bill. View text
Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries
Actions Overview (1)
|05/06/2020||Introduced in Senate|
05/06/2020 Introduced in Senate
All Actions (1)
|05/06/2020||Read twice and referred to the Committee on the Judiciary.|
Action By: Senate
05/06/2020 Read twice and referred to the Committee on the Judiciary.
|Committee / Subcommittee||Date||Activity||Reports|
|Senate Judiciary||05/06/2020||Referred to|
Subject — Policy Area:
One Policy Area term, which best describes an entire measure, is assigned to every public bill or resolution.
- Cardiovascular and respiratory health
- Civil actions and liability
- Drug safety, medical device, and laboratory regulation
- Emergency medical services and trauma care
- Health personnel
- Health technology, devices, supplies
- Infectious and parasitic diseases
- Intellectual property
- Licensing and registrations
- Medical tests and diagnostic methods
- Product safety and quality
Latest Summary (1)
Introduced in Senate (05/06/2020)
Facilitating Innovation to Fight Coronavirus Act
This bill provides immunity from civil liability to health care providers for certain actions taken during the COVID-19 (i.e., coronavirus disease 2019) public health emergency and lengthens the terms of certain medical patents related to the treatment of COVID-19.
Specifically, when testing for or treating COVID-19 during the public health emergency, a health care provider may not be held liable in any federal, state, or local civil proceeding for (1) using or modifying a medical device for an unapproved use or indication; (2) practicing without a license or outside of an area of specialty, if instructed to do so by an individual with such a license or within such an area of speciality; or (3) conducting the testing of, or providing treatment to, a patient outside of the premises of standard health care facilities.
Additionally, certain medical patents that are issued with respect to the treatment of COVID-19 are deemed not to begin until the termination of the presidential emergency declaration relating to COVID-19 and are extended for an additional 10 years.